



Lipomics Technologies, Inc. Hires Dr. Rebecca Baillie to Senior Research Biologist Position

SACRAMENTO, Calif., Feb. 18, 2003 — Lipomics Technologies, Inc., a privately owned company that specializes in lipid metabolite research and analysis services, today announced the hiring of Dr. Rebecca Baillie, to the position of senior research biologist. Dr. Baillie will be working with the scientific team to develop diagnostics and clinical disease markers.

Dr. Baillie, who has spent more than 20 years in lipid research, is an expert in the field of lipid control of metabolism. Prior to joining Lipomics, Baillie worked at Entelos, Inc., building large-scale simulation models of obesity and fat cells, and using them for drug discovery and biomarker research.

"I greatly appreciate the opportunity to join such an innovative organization as Lipomics because of its unique approach of lipid profiling," said Dr. Baillie. "Lipids have often been overlooked in the development of biomarkers and diagnostic tools. Yet, because lipids are such ubiquitous yet critical components of metabolism, they can provide incredible insights into the function of cells, and how that function is changed by the environment, genes, and diseases. For the first time, we have the ability to look at changes in all lipid metabolites at once and the potential of linking those changes with defined disease processes."

"I am delighted to have a person with Dr. Baillie's experience in lipid metabolism, obesity research, and drug development to join our Scientific group," said Dr. Steve Watkins, Lipomics' President and CEO. "Rebecca will be a tremendous asset to Lipomics as the company grows and develops into a mature biotechnology company. Lipids are a critical component of the metabolome, and are fundamental markers of health and disease. We're honored that she is joining us."

Lipomic Profiling

Lipomic profiling produces quantitative and comprehensive measurements of lipid metabolites in biological samples and uses this information to generate new understanding of human and animal health. Lipomic profiling can accurately describe an individual's actual response to a treatment. Now researchers can partner genomics or proteomics with lipomic profiling to more accurately predict and assess patient response to an intervention.

About Lipomics Technologies, Inc.

Lipomics Technologies, Inc. is a leading provider of quantitative and comprehensive lipid analyses and technologies that combine state-of-the-art technology for separation

and quantification of lipid metabolites with informatic systems for generating knowledge about lipid metabolism. Lipomics specializes in assessing lipid metabolism associated with cardiovascular disease, obesity and diabetes and offers a range of analytical, database, software and consulting services.

Safe Harbor Statement

Certain matters contained in this Lipomics Technologies, Inc. press release are forward looking statements that are subject to known risks and uncertainties, which may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements.

#

EDITORIAL CONTACTS:

Sarina Chohan
(916) 371-7974
schohan@lipomics.com

Media Contact

Doug Forsyth, Alchymia Communications
(541) 482-8744
df@alchymiacomm.com